Continuing Education Test Questions for
OSTEOPOROSIS
PREVENTION AND SCREENING:
POTENTIAL ROLE FOR ORAL
HEALTH PROFESSIONALS?
3 CEUs
This CE course is intended for dentists and dental hygienists. The cost of this course is $45 for 3 CEUs. The test and
personal information may be accessed and downloaded at www.thesystemiclink.com. Check the box that corre-
sponds to your answer. After completing the test, fill in the personal information on the next page and return the form
and test answers via either of two options:
1) Submit via U.S. Mail to:
Grand Rounds in Oral-Systemic Medicine^™
1421 S. Sheridan Road
Tulsa, OK 74112
2) Submit via fax to (⁹¹⁸) ⁸³¹-⁹⁸⁰⁴
For inquiries about the results of this Continuing Education Test, contact Machele Galloway at (800) 633-1681.

1. Which of the following are true for both osteoporosis
and periodontitis?
❏^a bone resorptive diseases mediated by proinflammatory
cytokines

❏^b dependent on host genetics and response

❏^c multifactorial etiology

❏^d predominantly affects older populations

❏^e all of the above

2. Which of the following is not true for osteoporosis?

❏^a more prevalent in postmenopausal women

❏^b affects more than 10 million people in the United States

❏^c risk factors do not include medications or other
systemic conditions
❏^d characterized by reduced bone strength, decreased bone
mineral density

❏^e all of the above

3. Which of the following is not true for implant therapy in
patients with osteoporosis?
❏^a osseointegration of implants in osteoporotic bone is
possible

❏^b long-term stability of implants may be compromised

❏^c dental implants are not a viable treatment option for
patients with osteoporosis
❏^d there have been reported implant failures in patients
with osteoporosis

❏^e all of the above

4. Comprehensive care and bi-directional management of
patients with osteoporosis and periodontal disease may
include which of the following?
❏^a clinical protocols that minimize further deterioration
of systemic or oral bony structures
❏^b intraoral radiography as a screening tool for osteopo-
rosis
❏^c placing patients with osteoporosis into “high risk”
periodontitis maintenance and recall
❏^d closely monitoring for signs of osteonecrosis in patients
taking bisphosphonates

❏^e all of the above

5. Current approaches to treating systemic/oral bone loss with chemotherapeutics do not include which of the following? ❏^a anti-resorptive agents ❏^b anabolic agents ❏^c bisphosphonates ❏^d stimulating bone resorption and inhibiting bone formation ❏^e all of the above

6. Which of the following is not true of bisphosphonates?
❏^a inhibit bone resorption through multiple mechanisms
❏^b major biological effects are on osteoclasts

❏^c they should not be used in patients with osteoporosis

❏^d there have been reports of significant side effects such
as osteonecrosis of the jaw

❏^e all of the above